Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects at the end of pregnancy ( 37-42 w ) at low risk of PPH Mean by low-risk of PPH subjects without any of the following risk factors : hypertension/preeclampsia, placental abruption during pregnancy , placenta previa , tocolysis two hours before delivery, multiple pregnancy , previous PPH, obesity ( BMI \> 35 ), anemia (Hb \< 7 g/dL), elective caesarean section , induction of labor, retention of placental material , polyhydramnios , fever during labor, use of high doses of heparin low molecular weight.~* Subjects full capacity and the willingness to give written informed consent .~Exclusion Criteria:~* Subjects with preterm pregnancy (\<37 weeks ) or with prolonged pregnancy ( \> 42 weeks )~* Subjects at the end of pregnancy ( 37 weeks - 42 weeks ) with the following risk factors for PPH (Tab1.Protocol Study, vers.2.0 of 07/05/2016)~* multiple pregnancy~* History of thromboembolic disease or high incidence of thromboembolic events in family history ( patients at high risk of thrombophilia )~* Patients with Long - QT syndrome or who are taking drugs that cause QT prolongation~* Intrauterine fetal Death~* Epilepsy~* Autoimmune disease Tab1 medical history :~* Placental abruption during pregnancy~* Placenta previa~* Hypertension / preeclampsia~* Previous PPH~* Polyhydramnios~* Obesity ( BMI \> 35 )~* Anemia ( \< 7 g / dL )

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- arm A (TXA) (Type: EXPERIMENTAL): 2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
- arm B (OXY) (Type: ACTIVE_COMPARATOR): 2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)

Based on this trial design, predict the completion outcome and termination type (if applicable).